When Your Supplier Gets Acquired: Managing Regulatory Continuity During M&A Activity
Date: April 29, 2026
Duration: 60 Minutes
Time: 12 PM EST
The pharmaceutical and biotech industries are no strangers to mergers, acquisitions, and corporate consolidations. But when the acquired entity is not a competitor – it is your CMO, CRO, IRT vendor, or API supplier – the regulatory stakes are immediate, complex, and often underestimated. Suddenly, the organization that signed your Quality Agreement, holds your raw material specifications, and is named in your IND or Marketing Authorization Application has a new parent company, new leadership, new systems, and potentially a new set of priorities.
The question that follows is urgent: What happens to your regulatory continuity?
The reality is that M&A activity in the life sciences supply chain is intensifying. Large CROs and CMOs have undergone significant consolidation in recent years, and companies that built regulatory strategies around a specific supplier relationship can find themselves exposed with little notice. From open INDs relying on sole-source excipient suppliers, to clinical trials running on platforms owned by acquirees mid-study, the downstream regulatory consequences of a supplier acquisition are far-reaching – and far too few organizations have formal plans to address them.
In this 60-minute expert-led webinar, a regulatory veteran with 20 years of hands-on FDA experience will walk you through the regulatory, quality, and operational dimensions of supplier M&A – equipping you with the frameworks and tools to protect your programs, your submissions, and your patients when the landscape shifts beneath you.
TOPICS TO BE COVERED
The Regulatory Risk Landscape of Supplier M&A
We open with an honest assessment of what is actually at stake when a supplier is acquired. This section covers how a change in supplier ownership qualifies as a reportable change under FDA and EMA frameworks, what constitutes a ‘major,’ ‘moderate,’ or ‘minor’ change, and why many companies fail to even track supplier M&A events in real time.
Impact on INDs, NDAs, BLAs, and Marketing Authorizations
A detailed review of how supplier acquisition triggers change control obligations in your existing regulatory filings — including which module sections need updating, how to assess whether a Prior Approval Supplement (PAS), Changes Being Effected (CBE), or Annual Report-level change is required, and how EMA’s variation framework handles supplier-level changes. Real-world filing scenarios will be used to anchor the discussion.
Quality Agreement Continuity: What Survives an Acquisition?
- Understanding assignment and assumption clauses in existing Quality Agreements
- Renegotiating GMP responsibilities when parent company systems don’t align
- Managing the gap period between acquisition close and new agreement execution
- Handling audit rights, right-to-inspect, and corrective action obligations under the new entity
Clinical Trial-Specific Risks: CROs, IRTs, and Clinical Supplies
For ongoing clinical trials, supplier M&A mid-study presents acute risks. This section covers notification obligations to IRBs and FDA, managing changes to IRT/IXRS vendors named in protocols, ensuring blinding integrity is not compromised, and clinical supply continuity planning when a CMO changes hands during active Phase II or III manufacturing runs.
Building a Supplier M&A Early Warning System
- How to monitor the corporate landscape for acquisition signals before close
- Contractual provisions that require supplier notification of M&A events
- Regulatory intelligence tools and services that track supplier ownership changes
- Integrating supplier M&A monitoring into your annual product review (APR) cycle
Regulatory Communication Strategy: When and How to Notify FDA and EMA
Not every acquisition requires immediate regulatory action — but knowing which ones do, and communicating proactively, can be the difference between a smooth transition and an enforcement issue. This section covers how to draft and time FDA and EMA notifications, when to request meetings, and how to present supplier transition data in a way that builds rather than erodes agency confidence.
Live Q&A with the Presenter
An open forum where attendees bring their own supplier scenarios, active programs, and organizational challenges for expert, real-time discussion.
WHY SHOULD YOU ATTEND?
Supplier M&A is one of the most disruptive and least-prepared-for events in the life sciences regulatory calendar. Most organizations lack a formal playbook for navigating it. The stakes span delayed submissions, FDA enforcement exposure, clinical hold risk, and compromised supply chains. This webinar gives you what most compliance frameworks overlook:
- A clear, regulatory-grounded understanding of exactly when and how supplier acquisitions trigger change control and submission obligations under FDA and EMA frameworks
- Practical, experience-backed strategies for protecting active INDs, NDAs, BLAs, and Marketing Authorizations when supplier ownership changes mid-program
- Proven frameworks for renegotiating Quality Agreements quickly, without creating compliance gaps during the transition period
- Tools to proactively monitor for supplier M&A events before they become emergencies — not after
- Guidance on how to communicate with FDA and EMA about supplier transitions in a way that reinforces your organization’s compliance posture rather than raising red flags
- A Certificate of Completion for professional development records
Whether you are currently managing a supplier transition, anticipating M&A disruption in your vendor base, or building proactive regulatory resilience into your supply chain strategy, this session will give you the regulatory vocabulary, decision frameworks, and practical tools to navigate it confidently.
WHO WILL BENEFIT?
This webinar is designed for experienced professionals who own or influence regulatory strategy, quality management, supply chain continuity, or clinical operations in drug development organizations. You will find this session most directly applicable if you work in one of the following roles:
- Regulatory Affairs Directors & Managers
- Drug Development Leaders
- Quality Assurance & Compliance Professionals
- Clinical Operations Leaders
- Supply Chain & Procurement Directors
- CMC Regulatory Specialists
- Alliance & Partnership Managers
- Regulatory Consultants & CRO Professionals
Speaker: Mukesh Kumar
PhD, RAC | CEO, FDAMap
For more info, fill the box below. We will contact you within 24 hrs.
Webinar Fee
Prices are in US Dollars.
The registration fee includes: The live webinar & all related course materials.
Terms & Conditions to register for the Webinar
Your Registration for the workshop is subject to following terms and conditions. If you need any clarification before registering for this webinar please email us at info@fdamap.com
Payment
We accept credit card, debit card, and PayPal.
Cancellations & Substitutions:
Written cancellations through fax or email (from the person who has registered for this conference) received at least 5 business days prior to the start date of the event will receive a refund — less a $30 administration fee. No cancellations will be accepted — nor refunds issued — within 5 business days before the start date of the event. You may however, choose to substitute the webinar for which you are registered with some other webinar in the future.
On request by email or fax (before the seminar) a credit for the amount paid minus administration fees ($30) will be transferred to any future FDA Map event and a credit note will be issued. No-shows will be charged the full amount.
Webinar material will be uploaded on the website 24 hours before the scheduled date of the webinar. In case it is not available on the website due to some technical issues, we will email the material a few hours before the start of the webinar.
In the event FDA Map cancels the webinar, FDA Map will issue a full refund to all the registrants for that webinar. Some topics and speakers may be subject to change without notice.
